The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.
Also called NCT02258074
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 205 participants
- Registry
-
NCT02258074
-
- Other papers using this trial's data
- Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial
- Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02258074. Randomized; triple masking; primary purpose other. Start 2015-03 (actual); primary completion 2018-11 (actual). Results posted on 2021-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
- Acronym
- COMBINE
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Nicotinamide
- Intervention (Drug)
- Lanthanum Carbonate
- Intervention (Drug)
- Placebo (for Nicotinamide)
- Intervention (Drug)
- Placebo (for lanthanum carbonate)
- Lead sponsor
- The Cleveland Clinic
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct02258074- Content hash
203d98a839131bc0fd65ccebb690322f2d9e81f083dd66332b0e041ce99647ce